Fluoride vs hydroxyapatite: stronger evidence or a promising alternative?

Fluoride remains the better-supported default for preventing cavities. Hydroxyapatite is a promising alternative, but it does not yet have the same depth of long-term clinical evidence. Some trials have found comparable results; that is not proof that every hydroxyapatite toothpaste protects every user equally well. Cochrane’s fluoride review and a 2025 hydroxyapatite review show this difference in the evidence base.

This comparison concerns daily toothpaste—not fluoride varnish, prescription products or drinking-water fluoridation.

Question	Fluoride toothpaste	Hydroxyapatite toothpaste
Cavity prevention	Supported by decades of trials and dental-association recommendations	Encouraging clinical results, with fewer trials and less long-term certainty
Early enamel mineral loss	Helps replace lost minerals and makes enamel more acid-resistant	Supplies calcium-phosphate particles that may support remineralization
Sensitivity	Depends on the formulation; stannous fluoride and other desensitizing ingredients can help	Can help block exposed dentin channels and reduce sensitivity
A hole or missing enamel	Cannot regrow missing tooth structure	Cannot regrow missing tooth structure

How they work—and what “repair” means

Enamel repeatedly loses and regains minerals. Acids made by plaque bacteria using dietary sugars drive mineral loss; saliva supplies calcium and phosphate that help replace it. Remineralization means restoring mineral to weakened tooth tissue, not growing a replacement tooth surface. NIDCR explains this decay process.

Fluoride encourages remineralization and helps make the repaired mineral more resistant to acid. It can also inhibit bacterial metabolism. Hydroxyapatite, often shortened to HAP, is a calcium-phosphate mineral similar to the mineral in teeth. In toothpaste, synthetic particles can attach to tooth surfaces and act as a source of calcium and phosphate. These are different routes toward protecting mineralized tissue—not a contrast between “repair” and “no repair.” ADA fluoride guidance; hydroxyapatite review.

Early decay may stop or partly reverse while the enamel surface remains intact. Once tissue has broken down into a true hole, neither ingredient rebuilds it. Our guide to whether cavities are reversible explains that boundary.

What the cavity-prevention studies actually show

Fluoride has the broader evidence base

A 2019 Cochrane review included 96 studies. It found high-certainty evidence that 1,000–1,250 parts per million (ppm) fluoride toothpaste reduced new decay compared with non-fluoride toothpaste in children’s and adolescents’ permanent teeth. Other findings, including benefit in adults, had moderate-certainty evidence. Most studies followed participants for about three years. These comparisons establish fluoride’s effectiveness; they do not directly establish its superiority to modern hydroxyapatite products. Cochrane review.

Hydroxyapatite has meaningful—but narrower—clinical evidence

An 18-month randomized trial published in 2023 compared 10% hydroxyapatite with 1,450 ppm fluoride in adults aged 18–45. Among 171 participants who completed the trial according to protocol, 89.3% in the hydroxyapatite group and 87.4% in the fluoride group had no increase in their decayed, missing or filled tooth-surface score. Hydroxyapatite met the trial’s definition of non-inferiority. Adult clinical trial.

Non-inferiority means the results ruled out the tested product being worse than the comparator by more than a prespecified margin, within the trial’s statistical confidence—not that the products were proved identical. The trial used a 20-percentage-point margin. It also excluded people with salivary disorders or medications affecting saliva, limiting what it tells us about dry-mouth-related decay. The study received manufacturer and university funding, and three authors were manufacturer employees. Those relationships do not invalidate the findings, but independent replication would strengthen confidence. Trial methods and disclosures.

Reviews have not reached uniformly confident conclusions. A 2022 systematic review of nano-hydroxyapatite found the evidence inconclusive because of study limitations. The 2025 review was more encouraging. It included four eligible trials, with follow-up ranging from six to 18 months; pooling two trials with comparable outcomes found no statistically significant difference in lesion development or progression. However, formulations varied and three studies had unclear risk of bias. One children’s trial used a 500 ppm fluoride comparator, so it does not establish equivalence to stronger fluoride toothpaste.

The practical interpretation is promising alternative, not universally established replacement. Findings for one concentration, particle type or formulation should not be transferred automatically to another product.

Sensitivity is a separate comparison

Dentin—the tissue beneath enamel—contains tiny channels. When exposed, fluid movement within those channels can trigger sensitivity. Hydroxyapatite can help block them. A 2023 systematic review found reduced sensitivity with HAP-containing products, although two authors were toothpaste-manufacturer employees.

That does not make all fluoride toothpastes inferior for sensitivity. Sodium fluoride toothpaste and a dedicated sensitivity toothpaste are different comparators. The ADA identifies evidence supporting formulations containing stannous fluoride, potassium with or without stannous fluoride, or arginine. Compare the whole formulation and its intended purpose, not just “fluoride versus fluoride-free.” ADA toothpaste guidance.

Safety and children: dose and formulation matter

The ADA considers fluoride safe and effective when used as directed. Repeatedly swallowing excess fluoride while teeth are developing can cause dental fluorosis, which changes enamel’s appearance. Its guidance is a rice-grain-sized smear of fluoride toothpaste from the first tooth until age three, then a pea-sized amount from ages three to six, with caregiver supervision to encourage spitting rather than swallowing. ADA fluoride guidance; ADA toothpaste guidance.

“Nano” describes very small hydroxyapatite particles; it is not by itself a safety verdict. In June 2025, the European Commission’s Scientific Committee on Consumer Safety concluded that the assessed nano-HAP was safe at up to 29.5% in toothpaste. That conclusion applies only to specified particle characteristics, including uncoated rod-shaped particles, and excludes needle-shaped material. It is a safety assessment—not proof of cavity prevention or blanket approval of every nano-HAP product. SCCS opinion.

What matters when choosing a toothpaste

• For routine cavity prevention: fluoride is the evidence-backed default. Over-the-counter fluoride toothpastes in the United States generally contain 1,000–1,500 ppm fluoride. Toothpastes carrying the ADA Seal for cavity protection must contain fluoride; that requirement does not prove HAP ineffective. ADA fluoride guidance; ADA Seal requirements.
• For someone declining fluoride: hydroxyapatite is a reasonable option to discuss with a dentist, with the evidence limits understood—particularly before replacing an existing decay-prevention plan. A July 2026 MUSC explanation makes this distinction.
• For a product containing both: check its fluoride concentration and product-specific evidence. Combining ingredients does not automatically establish added benefit; research remains developing. MUSC explanation.

Neither choice makes repeated sugar exposure harmless. Nor should cavity-prevention findings be treated as evidence that toothpaste reverses acid erosion: erosion comes from non-bacterial acids, and lost tooth substance is irreversible. NIDCR decay guidance; ADA erosion guidance.

Decay Guide is an independent information publisher, not a dental practice. This article provides general reference information, not individual diagnosis or treatment advice.